Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Jun;64(6):859-64.
doi: 10.1136/ard.2004.024463. Epub 2004 Nov 4.

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

A D Fraser  1 , A W R van Kuijk, R Westhovens, Z Karim, R Wakefield, A H Gerards, R Landewé, S D Steinfeld, P Emery, B A C Dijkmans, D J Veale
Affiliations
Clinical Trial

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

A D Fraser et al. Ann Rheum Dis. 2005 Jun.

Abstract

Objectives: To evaluate the safety and efficacy of adding ciclosporin A (CSA) to the treatment of patients with psoriatic arthritis (PsA) demonstrating an incomplete response to methotrexate (MTX) monotherapy.

Methods: In a 12 month, randomised, double blind, placebo controlled trial at five centres in three countries, 72 patients with active PsA with an incomplete response to MTX were randomised to receive either CSA (n = 38) or placebo (n = 34). Patients underwent full clinical and radiological assessment and, in addition, high resolution ultrasound (HRUS) was performed at one centre. An intention to treat (last observation carried forward) analysis was employed.

Results: Some significant improvements were noted at 12 months in both groups. However, in the active but not the placebo arm there were significant improvements in swollen joint count, mean (SD), from 11.7 (9.7) to 6.7 (6.5) (p<0.001) and C reactive protein, from 17.4 (14.5) to 12.7 (14.3) mg/l (p<0.05) as compared with baseline. The Psoriasis Area and Severity Index (PASI) score improved in the active group (2 (2.3) to 0.8 (1.3)) as compared with placebo (2.2 (2.7) to 1.9 (2.8)), p<0.001, and synovitis detected by HRUS (33 patients, 285 joints) was reduced by 33% in the active group compared with 6% in the placebo group (p<0.05). No improvement in Health Assessment Questionnaire or pain scores was detected.

Conclusions: Synovitis detected by HRUS was significantly reduced. Combining CSA and MTX treatment in patients with active PsA, and a partial response to MTX, significantly improves the signs of inflammation but not pain or quality of life.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in clinical, biochemical, and radiological measurements between baseline and 48 weeks. Significant changes from baseline are indicated (*p<0.05 and **p<0.001 for the active group; †p<0.05 and ††p<0.001 for the placebo group).
Figure 2
Figure 2
Percentage of joints with synovitis detectable by HRUS from baseline to 48 weeks. *p<0.05.
See this image and copyright information in PMC

References

    1. J Rheumatol. 2001 Oct;28(10):2274-82 - PubMed
    1. JAMA. 1964 Sep 7;189:743-7 - PubMed
    1. J Rheumatol. 2003 Feb;30(2):260-8 - PubMed
    1. BioDrugs. 2003;17(4):263-70 - PubMed
    1. N Engl J Med. 2003 Aug 14;349(7):658-65 - PubMed

Publication types